
Opinion|Videos|April 25, 2024
Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants 510(k) clearance to Break Wave lithotripsy device for kidney stones
2
CaverSTIM device shows initial promise for post-prostatectomy erectile dysfunction
3
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
4
John Sfakianos, MD, on moving immunotherapy earlier in NMIBC treatment pathway
5


















